Logo image of TLSA

TIZIANA LIFE SCIENCES LTD (TLSA) Stock Fundamental Analysis

NASDAQ:TLSA - BMG889121031 - Common Stock

1.81 USD
-0.02 (-1.09%)
Last: 8/29/2025, 8:00:01 PM
1.7807 USD
-0.03 (-1.62%)
After Hours: 8/29/2025, 8:00:01 PM
Fundamental Rating

2

TLSA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. While TLSA seems to be doing ok healthwise, there are quite some concerns on its profitability. TLSA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TLSA had negative earnings in the past year.
TLSA had a negative operating cash flow in the past year.
TLSA had negative earnings in each of the past 5 years.
In the past 5 years TLSA always reported negative operating cash flow.
TLSA Yearly Net Income VS EBIT VS OCF VS FCFTLSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

TLSA's Return On Assets of -105.13% is on the low side compared to the rest of the industry. TLSA is outperformed by 77.12% of its industry peers.
TLSA has a Return On Equity of -301.40%. This is in the lower half of the industry: TLSA underperforms 71.03% of its industry peers.
Industry RankSector Rank
ROA -105.13%
ROE -301.4%
ROIC N/A
ROA(3y)-83.77%
ROA(5y)-135.3%
ROE(3y)-151.66%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLSA Yearly ROA, ROE, ROICTLSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TLSA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLSA Yearly Profit, Operating, Gross MarginsTLSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, TLSA has more shares outstanding
TLSA has more shares outstanding than it did 5 years ago.
TLSA has a better debt/assets ratio than last year.
TLSA Yearly Shares OutstandingTLSA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TLSA Yearly Total Debt VS Total AssetsTLSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 9.69 indicates that TLSA is not in any danger for bankruptcy at the moment.
The Altman-Z score of TLSA (9.69) is better than 85.98% of its industry peers.
There is no outstanding debt for TLSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.69
ROIC/WACCN/A
WACCN/A
TLSA Yearly LT Debt VS Equity VS FCFTLSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.02 indicates that TLSA should not have too much problems paying its short term obligations.
With a Current ratio value of 1.02, TLSA is not doing good in the industry: 87.08% of the companies in the same industry are doing better.
A Quick Ratio of 1.02 indicates that TLSA should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.02, TLSA is doing worse than 86.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
TLSA Yearly Current Assets VS Current LiabilitesTLSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

TLSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.02%, which is quite impressive.
EPS 1Y (TTM)36.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TLSA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -10.06% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.33%
EPS Next 2Y-9.54%
EPS Next 3Y-10.06%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TLSA Yearly Revenue VS EstimatesTLSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 100M 200M 300M 400M 500M
TLSA Yearly EPS VS EstimatesTLSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLSA. In the last year negative earnings were reported.
Also next year TLSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLSA Price Earnings VS Forward Price EarningsTLSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLSA Per share dataTLSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15

4.3 Compensation for Growth

TLSA's earnings are expected to decrease with -10.06% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.54%
EPS Next 3Y-10.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TLSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TIZIANA LIFE SCIENCES LTD

NASDAQ:TLSA (8/29/2025, 8:00:01 PM)

After market: 1.7807 -0.03 (-1.62%)

1.81

-0.02 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-01 2025-07-01/amc
Earnings (Next)10-13 2025-10-13
Inst Owners2.73%
Inst Owner Change51.78%
Ins Owners43.06%
Ins Owner ChangeN/A
Market Cap201.74M
Analysts82.86
Price Target8.16 (350.83%)
Short Float %0.92%
Short Ratio1.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)166.67%
PT rev (3m)166.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 51.26
P/tB 51.26
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.13%
ROE -301.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.77%
ROA(5y)-135.3%
ROE(3y)-151.66%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z 9.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.02%
EPS Next Y13.33%
EPS Next 2Y-9.54%
EPS Next 3Y-10.06%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.99%
OCF growth 3YN/A
OCF growth 5YN/A